Weekly Mitoxantrone Therapy of Hodgkinʼs Disease, Non-Hodgkinʼs Lymphoma, and Chronic Lymphocytic Leukemia A Southeastern Cancer Study Group Trial
- 1 June 1987
- journal article
- research article
- Published by Wolters Kluwer Health in American Journal of Clinical Oncology
- Vol. 10 (3) , 194-195
- https://doi.org/10.1097/00000421-198706000-00002
Abstract
A weekly schedule of mitoxantrone was evaluated in chronic lymphoproliferative disorders. One of 11 patients with Hodgkin''s disease, 2 of 12 with favorable-histology non-Hodgkin''s lymphoma, 4 of 27 with unfavorable-histology non-Hodgkin''s lymphoma, and 1 of 11 with chronic lymphocytic leukemia showed a response. Since the use of a larger single dose every 3 weeks is well tolerated, simpler, and probably more effective, we do not recommend further evaluation of the weekly dose schedule.This publication has 1 reference indexed in Scilit:
- Phase II studies of mitoxantrone (dihydroxyanthracenedione) in the treatment of advanced colorectal carcinomaAmerican Journal of Clinical Oncology, 1984